CliffBio
small molecule

VIEKIRA PAK (COPACKAGED)

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

Loss of exclusivityOctober 2033latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameVIEKIRA PAK (COPACKAGED)
Active ingredientDASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR
StrengthEQ 250MG BASE;12.5MG, 75MG, 50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalDecember 2014
Marketing statusDISCN

Listed patents

PatentExpiresType
10201542October 2033product
9629841October 2033product
8685984September 2032use U-1840
8466159September 2032use U-1637
8492386September 2032use U-1840
8680106September 2032use U-1637
8691938April 2032substance, product
8686026June 2031product
9044480April 2031use U-1638
8420596April 2031substance, product
9006387June 2030use U-1687
8642538September 2029substance, product
8188104May 2029substance, product
8501238December 2028substance, product
9139536November 2028use U-1753

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found